906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III

Clinical manifestations risk factors and prognosis associated with central nervous system relapse after CAR T therapy for R R B cell non Hodgkin lymphoma A multi center analysis

Allogeneic stem cell transplant following CAR T cell therapy in relapsed refractory adult acute lymphoblastic leukemia A real world analysis

Do patients with classic Hodgkin s lymphoma treated with ABVD in low middle income countries have a higher risk of neutropenia febrile neutropenia without G CSF support a single center retrospective study

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin lymphoma in the United States A population based cohort study

Survival disparities by race and income among adolescents and young adults with acute lymphoblastic leukemia

Comparative neuropsychiatric outcomes of ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia A propensity matched real world cohort study

Impact of the CAR T era on survival in diffuse large B cell lymphoma A u S population based cohort study

Acalabrutinib vs zanubrutinib as first line therapy in CLL A propensity score–matched study

Time toxicity in ALL Quantifying home days among adults with acute lymphoblastic leukemia

Beyond ECOG Assessment of physical function enhances risk stratification prior to CAR T cell therapy

Incidence and impact of acute coronary syndrome on outcomes in chimeric antigen receptor T cell therapy Insights from a six year nationwide analysis

Outcomes of outpatient chimeric antigen receptor T cell therapy administration A single center experience at an urban hospital

Race does not impact chimeric antigen receptor T cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Early post infusion cytokine profiling predicts toxicity and outcomes in recipients of NexCAR19 Actalycabtagene Autoleucel A pilot study with point of care assay integration

Survival differences in metropolitan versus nonmetropolitan rural counties in the US An analysis according to rural urban continuum codes RUCC in the lymphoma epidemiology of outcomes LEO study cohort

Golidocitinib combined with CHOP in newly diagnosed peripheral T cell lymphoma Preliminary Results from A phase 1 2 clinical trial

Disparities in access to CAR T therapy in a Medicaid predominant population A Louisiana case study highlighting policy lag

Real world treatment patterns and patient characteristics of venetoclax combination time limited therapy for chronic lymphocytic leukemia

Real world outcomes of younger patients with chronic lymphocytic leukemia treated with first line BTK inhibitor or BCL2 inhibitor therapy

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs Real world data analysis

The academic center effect Better outcomes for patients with DLBCL

Patterns of care and outcomes in patients with large B cell lymphoma not treated with full dose anthracycline regimens Outcome analysis from the lymphoma epidemiology of outcomes LEO prospective cohort study

Patients with burkitt s lymphoma have a better survival probability if treated in an academic cancer program

Incidence and risk factors for immune effector cell associated neurotoxicity syndrome in older patients with relapsed or refractory large B cell lymphoma A multicenter study

Risk of hepatitis B virus reactivaton in HBsAg negative anti hbc positive patients receiving rituximab A systematic review

Blinatumomab efficacy differs between newly diagnosed and relapsed refractory B ALL Impact on MRD clearance and survival

Golidocitinib combination therapy as first line treatment in PTCL Retrospective data from a single centre

Real world experience with varnimcabtagene autoleucel murine CD19 CAR T from India A step towards enhanced patient access with excellent safety and efficacy

Dual anti HLH and antitumor efficacy of golidocitinib in relapsed refractory PTCL associated hemophagocytic lymphohistiocytosis A retrospective safety and activity analysis

Intrathecal chemotherapy for management of immune effector cell associated neurotoxicity syndrome ICANS A multi center real world analysis of clinical outcomes

A post marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T cell therapy using the FDA adverse event reporting system

Ocular adnexal non Hodgkin lymphoma among hispanic Latino population 18 years of experience

PET imaging biomarkers predict survival in peripheral T cell lymphoma A systematic review and meta analysis

Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma NLPHL England 2014 2021 Preliminary data from the uncover Study group

Persistent B cell aplasia predicts late severe infections after anti CD19 CAR T cell treatment in B cell lymphoma A methodological approach to long term safety reporting

Propensity score matched comparison of outcomes following treatment with pola R CHP versus R CHOP for diffuse large B cell lymphoma patients captured in a real world database

Effectiveness and safety of polatuzumab vedotin in real world clinical practice in Chinese patients with diffuse large B cell lymphoma POLAREAL An interim analysis from a prospective multicenter observational registry study

Association between adolescent and young adult AYA age acuity of illness at diagnosis and clinical trial enrollment among patients with hematologic malignancies at a pediatric center

Rehabilitation needs and predictors of functional outcomes following CAR T cell therapy in lymphoma and multiple myeloma

Tali cel is a safe and effective therapy in patients with Relapsed Refractory B cell non Hodgkin lymphoma that allows equitable access a real world experience from India

Evaluation of real world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Initial performance of pirtobrutinib Real world outcomes among CLL patients after prior covalent BTKi and BCL2i use

Outcomes of inpatient and outpatient chimeric antigen receptor T cell therapy CAR T in newly authorized treatment centers ATCs in the United States US

Changes in real world treatment patterns over time by patient characteristics and time burden of treatment in CLL SLL

Socioeconomic disadvantage as measured by area deprivation index ADI impacts survival in patients with relapsed refractory aggressive lymphoma treated with CART

Treatment funding source and educational level are important prognostic factors for patients with diffuse large B cell lymphoma in the state of São paulo Brazil Analysis of a large real world data

R mini CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL

Baseline characterization of nutrition counseling and modifiable cardiovascular risk factors among childhood cancer survivors through EHR linked data analytics

Progression free survival in patients with low health related quality of life treated with zanubrutinib versus ibrutinib monotherapy Post hoc analysis of the ALPINE trial

Disparities in survival and therapy access in AYA acute lymphoblastic leukemia A real world analysis of social determinants in a low and middle income country

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory R R large B cell lymphoma LBCL in the United States

Association between pre existing mental health history and higher risk of mental health outcomes post CAR t therapy in patients with hematologic malignancies

Real world evaluation of health care resource utilization clinical effectiveness and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient OP setting for R R large B cell lymphoma LBCL

National health systems characteristics and lymphoma outcomes A global analysis

Geriatric assessment in hematology GAH scale for survival prognostication and early treatment discontinuation in older adults Final results from the spanish hematogeriatric registry

Patient characteristics and treatment outcomes with Pola R CHP A real world study of patients with previously untreated diffuse large B cell lymphoma DLBCL in the United States US

Impact of frailty in survival of older patients with classical Hodgkin lymphoma A retrospective multicenter study from the spanish registry of lymphoma RELINF of the spanish group of lymphoma GELTAMO

Beyond the trial Real world CRS icans and healthcare burden of CAR T cell therapy across US oncology practices

Barriers and bridges Real world CAR T delivery across US oncology practices

Outcomes of CAR T cell therapies after prior treatment with fixed duration mosunetuzumab in patients with relapsed refractory B cell non Hodgkin lymphoma

Real world overall survival and time to next treatment among elderly United States Medicare beneficiaries with chronic lymphocytic leukemia in the front line setting